|
Cumulative Revenue for the First Three Quarters Reaches 160.4 Billion KRW... Increased Investment in New Facilities and R&D
2026.11.13
|
|---|
|
- Debt-to-equity ratio improved to 87.8%... Progress made in debt repayment and financial structure stabilization - Temporary decline in profitability due to the operation and trial production at a new facility, alongside expanded R&D investment
We announced on the 12th that its cumulative revenue for the first three quarters reached 160.4 billion KRW, marking a 6.5% increase compared to the same period last year. Net profit for the period stood at 9 billion KRW—a 10.1% year-on-year increase—with a net profit margin of 5.6%, reflecting a stable profit structure.
Operating profit was recorded at 2.2 billion KRW, a decrease from the same period last year. The company explained that this was due to a temporary rise in fixed costs following the launch of a new production facility, as well as increased investment in research and development (R&D) to secure future growth drivers.
To expand production capacity in line with global manufacturing guidelines, the company is currently operating both its existing and new facilities. The cost of goods sold (COGS) ratio increased due to a combination of factors, including fixed costs associated with this dual-facility operation, expenses related to trial production, and higher costs for raw materials and supplies driven by a strong exchange rate.
Furthermore, the company continues to scale up its R&D investment to lay the groundwork for future growth. R&D expenditures reached 7.9 billion KRW, an increase of 24.8% compared to the same period last year.
Our financial structure has become more stable. By proactively addressing interest rate volatility and shifts in the financial environment, the company has improved its financial soundness through ongoing debt repayment and effective management of receivables. Borrowings incurred during the construction of the new factory are being gradually reduced through partial early repayments, while equity has increased by 2.9 billion KRW, driven in part by a 7.6 billion KRW rise in retained earnings. Consequently, the debt-to-equity ratio improved by approximately 6.0 percentage points year-on-year to 87.8%, and the current ratio rose by 15.0 percentage points to 170.2%, ensuring stable liquidity.
We further stated, "We participated in CPHI Worldwide and Cosmoprof Asia (Hong Kong) to expand our presence in overseas markets for wellness injectables—specifically those targeting vitamins, immunity, metabolic diseases, and beauty." They added, "We plan to secure new growth momentum by exploring global markets and increasing our exports." |


Home